---
title: "UBS: TIGERMED's net profit last year was below expectations, focus on the recovery of new order prices this year"
description: "UBS released a research report indicating that TIGERMED's revenue for the fiscal year 2025 is expected to grow by 1% to 16%, but the net profit attributable to shareholders is expected to be between R"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274237721.md"
published_at: "2026-01-30T02:26:47.000Z"
---

# UBS: TIGERMED's net profit last year was below expectations, focus on the recovery of new order prices this year

> UBS released a research report indicating that TIGERMED's revenue for the fiscal year 2025 is expected to grow by 1% to 16%, but the net profit attributable to shareholders is expected to be between RMB 830 million and RMB 1.23 billion, which is below expectations. The company stated that the prices of newly signed orders are stabilizing but still declining, affecting profit margins. UBS is paying attention to signals of a recovery in the prices of newly signed orders in 2026 and has set a target price of HKD 57.1 with a "Buy" rating

UBS research report indicates that TIGERMED (03347.HK) has issued a performance forecast, expecting a year-on-year revenue growth of 1% to 16% for the fiscal year 2025, implying a year-on-year revenue growth of 6.4% to 72.9% in the fourth quarter, with a median increase of 39.6%, exceeding the bank's and market expectations. However, the net profit attributable to shareholders is expected to be between RMB 830 million and RMB 1.23 billion, representing a year-on-year increase of 105% to 204%, which is lower than the bank's and market expectations.

The company stated that the prices of new orders signed in 2025 are stabilizing but still declining year-on-year, putting pressure on profit margins. The company also emphasized that the demand for clinical research and development is recovering. UBS is focused on the signals of price recovery for new orders signed by TIGERMED in 2026, as well as management's guidance on revenue and profits for 2026. A target price of HKD 57.1 and a "Buy" rating are now given

### Related Stocks

- [03347.HK - TIGERMED](https://longbridge.com/en/quote/03347.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 读懂金银铜：培风客陈大鹏带你理解全球秩序重构下的资源品定价新机遇 | 3 月 15 日，原紫金矿业投资经理陈大鹏带你拆解全球金属定价新范式 | [Link](https://longbridge.com/en/news/276523437.md) |
| SK 会长崔泰源警告：AI 正在吞噬一切，今年千亿美元利润或瞬间变巨亏 | SK 会长崔泰源发出严厉警示：AI 正在吞噬一切，技术变革的剧烈波动让年度规划失去意义。虽然 SK 海力士预期利润飙升至 1000 亿美元，但市场扭曲、能源瓶颈及技术迭代正让行业陷入 “双刃剑” 困境，领先者亦难逃生存危机。 | [Link](https://longbridge.com/en/news/276526102.md) |
| 机构 “最超配” 闪迪，“最低配” 英伟达 | 据摩根士丹利最新的统计：“机构对美国大型科技股的低配程度是 17 年来最大的” 相比 2025 年 Q4 的标普 500 指数权重，“$NVDA 仍然是机构低配程度最大的大型科技股，其次是苹果、微软、亚马逊和博通，而存储巨头闪迪则是 “最超 | [Link](https://longbridge.com/en/news/276289765.md) |
| 领土问题首上谈判桌 俄乌博弈进入 “深水区” | 在日内瓦举行的俄美乌三方谈判中，领土问题首次被纳入讨论议程。谈判于 2 月 17 日至 18 日进行，俄方称谈判 “务实高效”，乌方表示讨论深入且具有实质意义，美方则称各方同意继续谈判。尽管各方均表示取得进展，但关于下一轮谈判的细节尚未公布 | [Link](https://longbridge.com/en/news/276289464.md) |
| 黄仁勋预告 “前所未见” 的芯片新品，下一代 Feynman 架构或成焦点 | 黄仁勋预告今年的 GTC 大会上发布” 世界从未见过” 的全新芯片产品，分析认为新品可能涉及 Rubin 系列衍生产品或更具革命性的 Feynman 架构芯片，市场预期 Feynman 架构将针对推理场景进行深度优化。 | [Link](https://longbridge.com/en/news/276310964.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.